Allergy

The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.

In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.

In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.

Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.

A multi-site qualitative study identifies communication, language, and access barriers standing in the way of removing incorrect penicillin allergy labels.

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

Deucrictibant XR reduced HAE attack rates by 83% versus placebo in the pivotal phase 3 CHAPTER-3 study across all 3 HAE types.

The FDA granted lonvo-z priority review for HAE, setting a PDUFA date of March 10, 2027 based on positive Phase 3 HAELO data.

Alpha-gal syndrome remains vastly underdiagnosed, with expanding tick geography and delayed reactions complicating recognition across specialties.

FDA actions, a WAO consensus update, and late-stage trial data in food allergy, anaphylaxis, CRSwNP, and EoE, all in this August 2026 recap.

Mahboobeh Mahdavinia, MD, PhD, discusses new FORWARD data showing peanut and shellfish allergies resolve far less often than milk, soy, or wheat.

The Phase 3 CROSSING trial showed tezepelumab improved histologic remission and dysphagia symptoms through week 52 in eosinophilic esophagitis.

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.

The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.

Brian Vickery, MD, discusses the mechanism, dose-escalation design, and outlook for a first-in-human microneedle immunotherapy trial for peanut allergy.

An international 35-expert Delphi panel reached consensus on 33 of 35 statements on precautionary allergen labelling reference doses.

A FORWARD cohort study of 1,359 children found race, income, health literacy, and neighborhood deprivation each predicted food allergy resolution.

This week's highlight includes phase 3 trial results across dermatology, cardiology, and pulmonology, and a major conference preview.

Lieberman discusses atypical anaphylaxis signs in infants and toddlers and why epinephrine remains underused.

In part 2, Lieberman discusses why caregivers hesitate to use epinephrine and what system-level changes could close the gap in infants and toddlers.

Rima Rachid, MD, discusses the purified MTT formulation, phase 2 trial design, and the gut bacteria driving protection against peanut allergy.

Rima Rachid, MD, explains how bile acid metabolism and Bacteroides colonization drive durable Treg cell induction after FMT for peanut allergy.

The bispecific TSLP/IL-13 inhibitor BEL512 met its primary endpoint and all secondary endpoints in adults with chronic rhinosinusitis with nasal polyps.